VRNA

Verona Pharma Plc

A biopharmaceutical company focused on respiratory diseases, Verona Pharma developed Ohtuvayre (ensifentrine), an inhaled treatment for chronic obstructive pulmonary disease (COPD) delivered through a standard nebulizer. The company traces its roots to research on a novel class of drugs that both relax airways and reduce inflammation, and it is headquartered in London with operations in the United States. Its name nods to the Italian city of Verona, home of Shakespeare's Romeo and Juliet, a nod to the company's founding story.

ADR representing ordinary shares

No Schedule 13D or 13G filings recorded.